In view of these observations, the current findings suggest that targeting EGFR and TGF-β may be important for normalizing tumor angiogenesis in the primary tumor and suppressing angiogenesis in metastatic lesions in PDAC. This evidence concerns the gene TGFB1 and neoplasm.